Bydureon Bcise

Active Ingredient(s): Exenatide Synthetic
FDA Approved: * October 20, 2017
Pharm Company: * ASTRAZENECA AB
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Bydureon Bcise Overview

Exenatide (marketed as Byetta, Bydureon) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) medication, belonging to the group of incretin mimetics, approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day.[1] A once-weekly injection has been approved ...

Read more Bydureon Bcise Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Byetta

Recent Bydureon Bcise Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Exenatide Synthetic
  • For Suspension, Extended Release: 2mg, 2mg/vial
  • Injection: 2mg, 300mcg/1.2ml (250mcg/ml), 300ugm/1.2ml (250ugm/ml), 300ugm/1.2ml(250ugm/ml), 600mcg/2.4ml (250mcg/ml), 600ugm/2.4ml (250ugm/ml), 600ugm/2.4ml(250ugm/ml)
  • Suspension, Extended Release: 2mg/0.85ml (2mg/0.85ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bydureon Bcise: (1 result)

Sorted by National Drug Code
  • 0310-6540 Bydureon Bcise 2 mg/.85ml Subcutaneous Injection, Suspension, Extended Release by Astrazeneca Pharmaceuticals Lp

Other drugs which contain Exenatide Synthetic or a similar ingredient: (3 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA